Compare
Outset Medical, Inc. vs Axogen, Inc. vs Iridex Corp vs electroCore, Inc.
| Latest fiscal year | Outset Medical, Inc. OM | Axogen, Inc. AXGN | Iridex Corp IRIX | electroCore, Inc. ECOR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-01-03 | 2025-12-31 |
| Revenue | $119.48M | $225.21M | $52.67M | $32.03M |
| Revenue growth (YoY) | +5.1% | +20.2% | +8.2% | +27.2% |
| Gross margin | 39.1% | 74.3% | 36.5% | 86.8% |
| Operating margin | -55.8% | -3.5% | -4.9% | -41.1% |
| Net margin | -68.3% | -7.0% | -8.4% | -43.6% |
| Net income | -$81.65M | -$15.70M | -$4.44M | -$13.97M |
| EPS (Diluted) | -$5.37 | -$0.34 | -$0.26 | -$1.65 |
| Operating cash flow | -$46.33M | $812.0K | -$2.12M | -$8.19M |
| Free cash flow | -$47.12M | -$2.93M | -$2.26M | -$8.25M |
| Cash & equivalents | $35.01M | $35.55M | $6.03M | $7.04M |
| Total assets | $264.50M | $221.69M | $29.15M | $18.67M |
| Total liabilities | $137.54M | $92.84M | $24.23M | $20.38M |
| Shareholders' equity | $126.95M | $128.85M | $4.92M | -$1.71M |
| Return on year-end equity | -64.3% | -12.2% | -90.1% | n/a |
| Shares outstanding | 18.17M | 47.20M | 17.31M | 8.00M |
Revenue, most recent five fiscal years
| Fiscal year | Outset Medical, Inc. | Axogen, Inc. | Iridex Corp | electroCore, Inc. |
|---|---|---|---|---|
| Latest | $119.48M Ended 2025-12-31 | $225.21M Ended 2025-12-31 | $52.67M Ended 2026-01-03 | $32.03M Ended 2025-12-31 |
| 1 year earlier | $113.69M Ended 2024-12-31 | $187.34M Ended 2024-12-31 | $48.67M Ended 2024-12-28 | $25.18M Ended 2024-12-31 |
| 2 years earlier | $130.38M Ended 2023-12-31 | $159.01M Ended 2023-12-31 | $51.87M Ended 2023-12-30 | $16.03M Ended 2023-12-31 |
| 3 years earlier | $115.38M Ended 2022-12-31 | $138.58M Ended 2022-12-31 | $56.97M Ended 2022-12-31 | $8.59M Ended 2022-12-31 |
| 4 years earlier | $102.60M Ended 2021-12-31 | $127.36M Ended 2021-12-31 | $53.90M Ended 2022-01-01 | $5.45M Ended 2021-12-31 |